Literature DB >> 29449512

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

Valentina Fanotto, Mario Uccello, Irene Pecora, Lorenza Rimassa, Francesco Leone, Gerardo Rosati, Daniele Santini, Riccardo Giampieri, Samantha Di Donato, Gianluca Tomasello, Nicola Silvestris, Filippo Pietrantonio, Francesca Battaglin, Antonio Avallone, Mario Scartozzi, Eufemia Stefania Lutrino, Davide Melisi, Lorenzo Antonuzzo, Antonio Pellegrino, Laura Ferrari, Roberto Bordonaro, Caterina Vivaldi, Lorenzo Gerratana, Silvia Bozzarelli, Roberto Filippi, Domenico Bilancia, Marco Russano, Giuseppe Aprile.   

Abstract

Entities:  

Year:  2018        PMID： 29449512      PMCID： PMC5813760          DOI： 10.1634/theoncologist.2017-0158erratum

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
2017;22:1463–1469; first published on August 31, 2017; http://dx.doi.org/10.1634/theoncologist.2017-0158 Francesco Leone's affiliation was incorrectly shown in the original publication of this article. This erratum corrects that error, and the online version of the article has been updated to show the correct affiliation: Medical Oncology, University of Turin, Candiolo Cancer Institute, FPO, IRCCS, Turin, Italy.
  4 in total

1.  A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial.

Authors:  Valeria Merz; Camilla Zecchetto; Francesca Simionato; Alessandro Cavaliere; Simona Casalino; Michele Pavarana; Simone Giacopuzzi; Maria Bencivenga; Anna Tomezzoli; Raffaela Santoro; Vita Fedele; Serena Contarelli; Irene Rossi; Serena Giacomazzi; Martina Pasquato; Cristiana Piazzola; Stefano Milleri; Giovanni de Manzoni; Davide Melisi
Journal:  Ther Adv Med Oncol       Date:  2020-07-07       Impact factor: 8.168

Review 2.  Beyond the Beyond: A Case of an Extraordinary Response to Multiple Lines of Therapy in a de novo Metastatic HER2-Negative Gastric Cancer Patient.

Authors:  Cinzia Baldessari; Fabio Gelsomino; Andrea Spallanzani; Giuseppe Pugliese; Luca Reggiani Bonetti; Stefania Bettelli; Stefano Cascinu
Journal:  Gastrointest Tumors       Date:  2018-07-27

3.  Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma.

Authors:  Daniel V T Catenacci; Drew Rasco; Jeeyun Lee; Sun Young Rha; Keun-Wook Lee; Yung Jue Bang; Johanna Bendell; Peter Enzinger; Neyssa Marina; Hong Xiang; Wei Deng; Janine Powers; Zev A Wainberg
Journal:  J Clin Oncol       Date:  2020-03-13       Impact factor: 44.544

4.  Stenting as a bridge to surgery for extra-colonic malignancy induced colorectal obstruction: preliminary experience.

Authors:  Eui Joo Kim; Sang Hoon Han; Kyoung Oh Kim; Jun-Won Chung; Dong Kyun Park; Kwang An Kwon; Jung Ho Kim
Journal:  BMC Gastroenterol       Date:  2020-04-19       Impact factor: 3.067
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.